Cortexyme Provides Business Update and Reports Second Quarter 2021 Results

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $CRTX--Cortexyme, Inc. (Nasdaq: CRTX), a company advancing a pivotal trial in Alzheimer’s disease with top-line data expected by mid-November 2021 and a growing pipeline of therapeutics for degenerative diseases, today provided an update on expected clinical top-line data and reported second quarter 2021 financial results....

Click to view original post